The use of hydralazine to manipulate tumour temperatures during hyperthermia
- 1 January 1990
- journal article
- research article
- Published by Taylor & Francis in International Journal of Hyperthermia
- Vol. 6 (6) , 971-983
- https://doi.org/10.3109/02656739009140980
Abstract
Hydralazine is an antihypertensive drug which theoretically could increase tumour temperatures during hyperthermia via reduction in tumour blood flow from a vascular ‘steal’ phenomenon. Doses that are therapeutically effective in reducing blood pressure in hypertensive patients would probably cause postural hypotension and other side-effects in normotensive patients beyond the hyperthermia treatment session, however. This study was designed to evaluate whether hydralazine, when administered at a safe dose for monnotensive patients (0·125 mg/kg, i.v.) would be effective in increasing tumour temperatures during hyperthermia. The working hypothesis was that hydralazine at a dose of 0·25 mg/kg would be effective in raising tumour temperatures during hyperthermia treatment with minimal change in blood pressure. Fourteen human and five canine subjects were given hydralazine (0·125 mg/kg, i.v.) at the midpoint of a hyperthermia session. Temperatures and blood pressures were monitored before and after drug administration. Although hydralazine resulted in slight reduction in blood pressure, it was ineffective in increasing tumour temperatures in human patients (average maximum rise inmedian temperature was 0·26±0·32°C). In canine subjects the same dose of hydralazine was effective in reducing blood pressure in four of five subjects studied (mean maximum drop was 22·7 ± 4·1 rnmHg) and the median temperature rose 0·8 ± 0·7 °C. In the canine subjects the greater the decrease in blood pressure, the greater the increase in temperature. These results suggest that a rise in tumour temperature induced by hydralazine is dependent on creating a drop in blood pressure. Future studies in this laboratory will include tumour blood flow manipulation with antihypertensives which have a shorter half-life and a titratable effect. Using this approach, hypotension, which seems to be required to raise tumour temperature, will be more controllable in terms of magnitude and duration.Keywords
This publication has 20 references indexed in Scilit:
- Blood perfusion measurements in human tumours: Evaluation of laser Doppler methodsInternational Journal of Hyperthermia, 1990
- Effects of hydralazine on in vivo tumor energy metabolism, hematopoietic radiation sensitivity, and cardiovascular parametersInternational Journal of Radiation Oncology*Biology*Physics, 1989
- Winner of the 1988 Lund Science Award: Hydralazine-induced enhancement of hyperthermic damage in a C3H mammary carcinomain vivoInternational Journal of Hyperthermia, 1989
- Effects of Hydralazine-Induced Vasodilation on the Energy Metabolism of Murine Tumors Studied by In Vivo31P-Nuclear Magnetic Resonance Spectroscopy1JNCI Journal of the National Cancer Institute, 1988
- Chemical modification of tumour blood flowInternational Journal of Hyperthermia, 1988
- The effect of hydralazine dose on blood perfusion changes during hyperthermiaInternational Journal of Hyperthermia, 1988
- Automated temperature scanning for hyperthermia treatment monitoringInternational Journal of Radiation Oncology*Biology*Physics, 1987
- Tumour microcirculation as a target for hyperthermiaInternational Journal of Hyperthermia, 1986
- Adaptation to low pH modifies thermal and thermo-chemical responses of mammalian cellsInternational Journal of Hyperthermia, 1986
- The Effect of Several Different Anaesthetics on the Blood Pressure and Heart Rate of the Mouse and on the Radiation Response of the Mouse Sarcoma RIF-1International Journal of Radiation Biology, 1985